Pac Premier
Giving Guide
You are here:  Home  >  Columns  >  Current Article

Has Amgen solved its conundrum?

By   /   Monday, June 7th, 2010  /   Comments Off on Has Amgen solved its conundrum?

    Print       Email

For the past decade, the world’s biggest biotechnology company has faced what I have come to call the Amgen conundrum.

The company’s revenue and profits keep rising, along with new ways of delivering its core drugs Epogen and Aranesp. But big one ingredient has been missing — a rising share price.

After a spectacular rise for nearly 15 years beginning in the mid-1980s, since 1999 Amgen has largely been stuck in a trading range of $50 to $85 per share, recently trading near the bottom of the range.

The full version of this column is only available in the print edition. To view everything the Business Times offers, see this week’s print version or SUBSCRIBE to the print edition for $49.99 today.

    Print       Email

You might also like...

Real Estate: With drought looming, Cayucos gets 420,000 gallons of new water storage

Read More →